Please assess the completion status of the following clinical trial:

Trial Title: Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between the ages of 18-65~* Sustained a physical injury with a pain score ≥ 5 on the numeric rating scale \[NRS\] from 0- 10 with anchors of 0 = no pain and 10 = worst pain imaginable~* Expected to be in the ED for at least 2 hours, in a private treatment room~* Ownership of a cell phone with text messaging capabilities~* Emergency Department admission assessment confirmed subject is not suicidal.~Exclusion Criteria:~* Non-English speaking~* Not medically suitable for lorazepam per treating MD (e.g. medical condition where benzodiazepines are contraindicated or may be unsafe)~* Not alert and oriented~* Active psychosis, self-injury, suicidal/homicidal intentions on initial evaluation by treating team~* Seeking treatment due to a mental health or substance use disorder~* History of chronic opioid use~* Prescribed opioid or benzodiazepine use within the past 24 hours~* Alcohol use within the past 12 hours or medical history of alcoholism.~* Clinical indication for open-label benzodiazepine administration in the ED.~* Any use of recreational narcotics throughout lifetime~* Sensitivity or allergy or intolerance to opioids or benzodiazepines~* Current neurological disease (e.g., multiple sclerosis, stroke, brain tumor, seizure disorder, etc.)~* Prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Drug: Oral Lorazepam (1mg) (Type: EXPERIMENTAL): Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
- Drug: Oral Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).